VERTEX PHARMACEUTICALS INC MA

For the period ended Sep 30, 2024. Filed Nov 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 5, 2024

VRTX$550.87+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Statements of Income -

Condensed Consolidated Statements of Income

(in millions, except per share amounts)(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Product revenues, net	$2,771.9	$2,483.5	$8,108.1	$7,351.5
Costs and expenses:
Cost of sales	392.6	318.7	1,107.1	894.2
Research and development expenses	875.9	810.0	2,631.6	2,338.3
Acquired in-process research and development expenses	15.0	51.7	4,540.9	509.3
Selling, general and administrative expenses	371.8	263.8	1,086.7	767.5
Change in fair value of contingent consideration	0.3	1.2	0.7	(1.3)
Total costs and expenses	1,655.6	1,445.4	9,367.0	4,508.0
Income (loss) from operations	1,116.3	1,038.1	(1,258.9)	2,843.5
Interest income	132.2	167.9	469.9	435.2
Interest expense	(7.5)	(10.9)	(27.8)	(33.5)
Other expense, net	(16.9)	(15.9)	(71.2)	(13.0)
Income (loss) before provision for income taxes	1,224.1	1,179.2	(888.0)	3,232.2
Provision for income taxes	178.7	143.9	560.6	581.4
Net income (loss)	$1,045.4	$1,035.3	$(1,448.6)	$2,650.8
Net income (loss) per common share:
Basic	$4.05	$4.01	$(5.61)	$10.29
Diluted	$4.01	$3.97	$(5.61)	$10.18
Shares used in per share calculations:
Basic	258.0	258.0	258.1	257.7
Diluted	261.0	260.6	258.1	260.4

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.